Next 10 |
home / stock / drma / drma articles
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Eme...
MIAMI, Feb. 07, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emer...
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results ...
Dermata Therapeutics Inc (NASDAQ: DRMA) stock was trading higher Friday after the company announced the issuance of a new patent in Japan for ...
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent i...
Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings. Children'...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.40% to 34...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. Seres Therapeutics, Inc. (NASDAQ: MCRB) climbed 45.9% to $1.20. Seres Ther...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...